美国放射学会甲状腺影像报告与数据系统的诊断效能:系统综述与Meta分析
该系统综述与Meta分析纳入16项研究共18,614例患者、21,882个甲状腺结节,评估ACR TI-RADS对甲状腺结节风险分层的诊断效能。汇总敏感度为0.89(95%CI 0.81-0.93),特异度为0.70(95%CI 0.60-0.78),汇总ROC曲线下面积为0.86(95%CI 0.83-0.89)。与ATA指南比较,ACR TI-RADS特异度较高但差异未达统计学显著;与韩国TIRADS比较,ACR TI-RADS特异度较低但敏感度无显著差异。作者认为ACR TI-RADS可避免大量不必要的活检,但以敏感度轻度下降为代价。
要点
- ACR TI-RADS汇总敏感度0.89、特异度0.70,诊断比值比18.46(95%CI 9.77-34.88)。
- 与ATA指南头对头比较,敏感度0.83 vs 0.87(p=0.5),特异度0.69 vs 0.50(p=0.1),均未达统计学显著。
- 与韩国TIRADS比较,特异度0.57 vs 0.24(p<0.001),敏感度0.85 vs 0.91(p=0.13)。
核心结论
- ACR TI-RADS在甲状腺结节风险分层中表现出良好的敏感度和中等特异度,使用ACR TI-RADS可避免大量不必要的活检,但以敏感度轻度下降为代价。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、Cochrane Library、Web of Science和Google Scholar截至2019年7月31日发表的文献,纳入16项研究共18,614例患者、21,882个结节,参考标准为超声引导下细针穿刺活检细胞学结果和/或手术切除病理结果。
诊断标准与关键数值
- ACR TI-RADS汇总敏感度0.89(95%CI 0.81-0.93),汇总特异度0.70(95%CI 0.60-0.78)。
- 汇总ROC曲线下面积0.86(95%CI 0.83-0.89),诊断比值比18.46(95%CI 9.77-34.88)。
- ACR TI-RADS与ATA指南比较:敏感度0.83 vs 0.87(p=0.5),特异度0.69 vs 0.50(p=0.1)。
- ACR TI-RADS与韩国TIRADS比较:敏感度0.85 vs 0.91(p=0.13),特异度0.57 vs 0.24(p<0.001)。
临床应用与阅片要点
- 作者认为使用ACR TI-RADS可避免大量不必要的活检,但以敏感度轻度下降为代价。
局限性
- Meta回归显示患者数量是异质性的显著因素(p=0.02)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The objective of our study was to investigate the diagnostic performance of the American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS) in the risk stratification of thyroid nodules. MATERIALS AND METHODS. A literature search of MEDLINE, Embase, Cochrane Library, Web of Science, and Google Scholar was performed for articles published before July 31, 2019. We included studies using ACR TI-RADS for stratification of thyroid nodules and cytology results from ultrasound-guided fine-needle aspiration biopsy (FNAB), pathology results from surgical resection of the thyroid, or both FNAB cytology and surgical pathology results as the reference standard. Summary estimates of sensitivity and specificity were calculated with the bivariate random-effects modeling and are visually presented in forest plots. We performed multiple subgroup analyses and meta-regression to explore the effects of various clinical settings. We compared ACR TI-RADS with the American Thyroid Association (ATA) guidelines and Korean Thyroid Imaging Reporting and Data System (TIRADS) in studies providing head-to-head comparison. RESULTS. Sixteen studies with 18,614 patients involving a total of 21,882 nodules, were included. The pooled sensitivity and specificity of ACR TI-RADS were 0.89 (95% CI, 0.81-0.93) and 0.70 (95% CI, 0.60-0.78), respectively. The calculated area under summary ROC curve was 0.86 (95% CI, 0.83-0.89), with a diagnostic odds ratio of 18.46 (95% CI, 9.77-34.88). Meta-regression revealed that patient number was a significant factor for heterogeneity (p = 0.02). Ten studies compared the performance of ACR TI-RADS and ATA guidelines: The pooled sensitivity was 0.83 versus 0.87 (p = 0.5), respectively, and the pooled specificity was 0.69 versus 0.50 (p = 0.1). In six studies providing direct comparison of ACR TI-RADS and Korean TIRADS, the pooled sensitivity was 0.85 versus 0.91 (p = 0.13), and the pooled specificity was 0.57 versus 0.24 (p < 0.001). CONCLUSION. ACR TI-RADS showed favorable sensitivity and moderate specificity in risk stratification of thyroid nodules. The use of ACR TI-RADS could avoid a large number of unnecessary biopsies, although at the cost of a slight decline in sensitivity.
引用
- Li W, Wang Y, Wen J, et al. Diagnostic Performance of American College of Radiology TI-RADS: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2020. PMID: 32603229. doi:10.2214/AJR.19.22691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。